Betting on the liver disease treatment sector, Novo Nordisk AS spent $5.2 billion to acquire Akero Therapeutics
Wallstreetcn·
- Novo Nordisk has agreed to acquire Akero Therapeutics for up to $5.2 billion to enhance its position in the treatment of metabolic diseases related to obesity.
- The acquisition includes a cash offer of $54 per share, representing a 16% premium over Akero's recent closing price, with additional payments contingent on regulatory approval of Akero's drug by June 30, 2031.
- This move, led by new CEO Mike Doustdar, aims to address competitive pressures in the obesity market and aligns with the company's strategy to develop therapies for related conditions like MASH.